🇺🇸 FDA
Pipeline program

LY3471851

17287

Phase 2 small_molecule terminated

Quick answer

LY3471851 for Colitis, Ulcerative is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Colitis, Ulcerative
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials